Antiretroviral drug levels and interactions affect lipid, lipoprotein, and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic- pharmacodynamic analysis

Metabolic Syndrome and Related Disorders

Volumn 5, Issue 2, 2007, Pages 163-173

  Rosenkranz, Susan L ^a,f   Yarasheski, Kevin E ^b   Para, Michael F ^c   Reichman, Richard C ^d   Morse, Gene D ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; C PEPTIDE; CHOLESTEROL; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34250731260     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2006.0034     Document Type: Article

References (48)

1. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003;33:571-576.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Copper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
3. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, Tofler GH, Grinspoon SS; Framingham Heart Study. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001;86:939-943.
4. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2002;87:4611-4615.
5. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13: 2493-505.
6. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS; International AIDS Society-USA. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257-275.
7. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-F67.
8. Yarasheski KE, Marin D, Claxton S, Powderly WG. Endocrine, Metabolic, and Body Composition Disorders, Manual of HIV Therapeutics, Powderly W.G., Ed., Philadelphia: Lippincott, Williams & Wilkins; 2001.
9. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, Halban PA, Cryer PE, Powderly WG. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999; 21:209-216.
10. Yarasheski KE, Tebas P, Stanerson B, Claxton S, Marion D, Bae K, Kennedy M, Tantisiriwat W, Powderly WG. Resistance exercise training increases muscle mass and strength and reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol 2001;90:133-138.
11. Bozzette SA, Ake CF, Tam HK, Change SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. New Engl J Med 2003;348:702-710.
12. Coudray N, de Zuttere D, Force G, Champetier de Ribes D, Pourny JC, Antony I, Lecarpentier Y, Chemla D. Left ventricular diastolic function in asymptomatic and symptomatic human immunodeficiency virus carriers: An echocardiographic study. Eur Heart J 1995;16:61-67.
13. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. New Engl J Med 2003;349: 1993-2003.
14. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32: 130-139.
15. Klein D, Hurley LB, Quesenberry CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471-477.
16. Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. New Engl J Med 2003;348: 679-680.
17. Martinez-Garcia T, Sobrino JM, Pujol E, Galvez J, Benitez E, Giron-Gonzalez JA. Ventricular mass and diastolic function in patients infected by the human immunodeficiency virus. Heart 2000;84:620-624.
18. Milei J, Grana D, Alonso GF, Matturri L. Cardiac involvement in acquired immunodeficiency syndrome - a review to push action. The Committee for the Study of Cardiac Involvement in AIDS. Clin Cardiol 1998;21:465-172.
19. Panther LA. How HIV infection and its treatment affects the cardiovascular system: What is known, what is needed. Am J Physiol Heart Circ Physiol 2002;283: H1-H4.
20. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993;144:225-231.
21. Prendergast BD. HIV and cardiovascular medicine. Heart 2003;89:793-800.
22. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000;40:282-284.
23. Shankar SS, Dubé MP. Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovasc Toxicol 2004;4:261-269.
24. Sklar P, Masur H. HIV infection and cardiovascular disease - Is there really a link? New Engl J Med 2003;349:2065-2067.
25. Wohl DA. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV infection and its therapies. Top HIV Med 2004;12:89-93.
26. Yunis NA, Stone VE. Cardiac manifestations of HIV/AIDS: A review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:145-154.
27. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002;15:F1-F8.
28. Schwarz JM, Lee GA, Park S, Noor MA, Lee J, Wen M, Lo JC, Mulligan K, Schambelan M, Grunfeld C. Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004;8:1852-1854.
29. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, Fiedorek FT, Haas DW. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004;18:2137-2144.
30. Lee G, Seneviratne T, Noor M, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004;18:641-649.
31. Purnell J, Zambon A, Knopp R, Pizzuti DJ, Achari R, Leonard JM, Locke C, Brunzell JD. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51-57.
32. Clevenbergh P, Garraffo R, Dellamonica P. Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients. HIV Clin Trials 2003;4: 330-336.
33. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P; D:A:D Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-1074.
34. Negredo E, Ribalta J, Ferre R, Salazar J, Rey-Joly C, Sirera G, Masana L, Clotet B. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. [Letter]. AIDS 2004;18:819-821.
35. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy N. Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011-1019.
36. Tebas P, Yarasheski KE, Henry K, Claxton S, Kane E, Bordenave B, Klebert M, Powderly WG. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruse 2004;20:589-594.
37. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJP, Schechter M, Murphy RL, Horban A, Hall DB, Lange JMA, Reiss P. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1:e19.
38. Morse GD, Rosenkranz S, Para MF, Segal Y, Difrancesco R, Adams E, Brizz B, Yarasheski KE, Reichman RC. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir or saquinavir. Antimicrob Agents Chemother 2005;49:3373-3381.
39. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
40. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497.
41. McCullagh P, Nelder JA. Generalized Linear Models, Second Edition. New York: Chapman and Hall; 1989: 33-36,118-119.
42. SUSTIVA® (efavirenz) capsules and tablets [prescribing information]. Bristol-Meyers Squibb Company, February 2002. Available at: http:www.sustiva. com.
43. Dubé MP, Qian D, Edmondson-Melancon H, Sattler FR, Goodwin D, Martinez C, Williams V, Johnson D, Buchanan TA. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002;35:475-481.
44. Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, Thiry A, Soccodato M, Noor MA, Giordano M. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in anti-retroviral-naive HIV-infected patients. Clin Infect Dis 2005;42:273-280.
45. Carpentier A, Patterson BW, Uffelman KD, Salit I, Lewis GF. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 2005;178:165-172.
46. Reeds DN, Mittendorfer B, Patterson BW, Powderly WG, Yarasheski KE, Klein S. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab 2003;285:E490-E497.
47. Pedneault L, Hanson C, Nacci P, Fetter A, Millard J, Rogers M. Amprenavir: A new protease inhibitor with a favorable metabolic profile. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Infection. 26-29 June 1999, San Diego, CA, USA. Abstract 034.
48. Pedneault L, Brothers C, Pagano G, Tymkewycz P, Yeo J, Millard J, Fetter A. Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. Clin Ther 2000; 22:1378-1394.